From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift

Jim Yong Kim; Joia S Mukherjee; Michael L Rich; Kedar Mate; Jaime Bayona; Mercedes C Becerra

doi:10.1016/s1472-9792(02)00078-1

From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift

Tuberculosis (Edinb). 2003;83(1-3):59-65. doi: 10.1016/s1472-9792(02)00078-1.

Authors

Jim Yong Kim¹, Joia S Mukherjee, Michael L Rich, Kedar Mate, Jaime Bayona, Mercedes C Becerra

Affiliation

¹ Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA 02115, USA. jim_yong_kim@hms.harvard.edu

PMID: 12758190
DOI: 10.1016/s1472-9792(02)00078-1

Abstract

This review examines the paradigm shift around multidrug-resistant tuberculosis (MDR-TB). This shift has centered largely on the activities of institutions participating in the World Health Organization's Working Group on DOTS-Plus for MDR-TB. We review the important milestones since 1995, namely, the emergence of new evidence, the construction of new mechanisms, and the building of consensus to support new policy guidelines. This paper offers a case study of the construction of a model of good global governance that--if the opportunity is taken--can improve access to effective TB care through improving and helping to expand the WHO-recommended DOTS strategy.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antitubercular Agents / therapeutic use*
Directly Observed Therapy / trends*
Evidence-Based Medicine
Humans
International Cooperation
Practice Guidelines as Topic
Tuberculosis, Multidrug-Resistant / drug therapy*
Tuberculosis, Pulmonary / drug therapy*

Substances

Antitubercular Agents